Advertisement

 

 

Treatment for Stage I NSCLC Patients Up From 2000 to 2010

Treatment for Stage I NSCLC Patients Up From 2000 to 2010
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

FRIDAY, Oct. 27, 2017 (HealthDay News) — For patients with stage I non-small-cell lung cancer (NSCLC), the odds of receiving radiation therapy (RT) or surgery increased from 2000 to 2010, with improved survival during the same period, according to a study published online Oct. 26 in the Annals of Thoracic Surgery.

Nirav S. Kapadia, M.D., from Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, and colleagues conducted a population-based comparative effectiveness study using Surveillance, Epidemiology, and End Results-18 data from 2000 to 2010 for stage I NSCLC patients. A total of 40,589 patients (62 percent) underwent surgery, 10,048 (15 percent) received RT, 2,130 (3 percent) received both surgery and RT, and 11,537 (18 percent) received neither surgery nor RT.

The researchers found that there was an increase annually in the odds of either receiving definitive RT or undergoing surgery relative to the odds of receiving no treatment (odds ratios, 1.04 and 1.05, for RT and surgery, respectively). The proportion of sublobar resections increased steadily among surgical patients, from 12.9 to 17.9 percent. Each year there was a 3.5 percent decrease in the two-year risk of death for all patients (hazard ratio, 0.965), driven mainly by improved survival for surgical and RT patients (annualized hazard ratios, 0.959 and 0.942, respectively).

“Between 2000 and 2010, stage I NSCLC patients were more likely to receive definitive treatment with either surgery or RT, leading to a decline in the number of untreated patients,” the authors write.

Abstract/Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.
healthday

Submit a Comment

Your email address will not be published. Required fields are marked *

3 × two =

[ HIDE/SHOW ]